for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Suven Life Sciences Ltd.

SUVP.NS

Latest Trade

100.10INR

Change

-4.60(-4.39%)

Volume

798,835

Today's Range

98.15

 - 

106.95

52 Week Range

43.95

 - 

124.45

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
104.70
Open
105.35
Volume
798,835
3M AVG Volume
23.08
Today's High
106.95
Today's Low
98.15
52 Week High
124.45
52 Week Low
43.95
Shares Out (MIL)
127.28
Market Cap (MIL)
13,326.48
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q2 2022 Suven Life Sciences Ltd Earnings Release

Latest Developments

More

Suven Life Sciences Announces Phase 3 Clinical Trial Of SUVN-502

Suven Life Sciences Says March-Quarter Consol Net Loss Narrows

India's Suven Life Sciences June-Qtr Consol Net Loss Narrows

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Suven Life Sciences Ltd.

Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3,4-dichlorobenzylamine. The Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.

Industry

Biotechnology & Drugs

Contact Info

SDE Serene Chambers 6th Floor

Road No. 5 Avenue 7, Banjara Hills

500034

India

+91.40.23541142

http://www.suven.com/

Executive Leadership

Venkateswarlu Jasti

Executive Chairman of the Board, Chief Executive Officer

P. Subba E. Rao

Chief Financial Officer

Shrenik Soni

Compliance Officer, Company Secretary

Sudha Rani Jasti

Wholetime Director

M. Gopalakrishna

Non-Executive Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
94.81
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Suven Pharmaceuticals March Quarter Consol Profit Falls

* SUVEN PHARMACEUTICALS - MARCH QUARTER CONSOL NET PROFIT 741.8 MILLION RUPEES VERSUS 748.2 MILLION RUPEES

BRIEF-Suven Pharmaceuticals Ltd -Damage Due To Fire To All Equipments, Furniture & Fixtures Is Estimated To Be About 180 Million Rupees And Is Fully Insured

* SUVEN PHARMACEUTICALS LTD -DAMAGE DUE TO FIRE TO ALL EQUIPMENTS, FURNITURE & FIXTURES IS ESTIMATED TO BE ABOUT 180 MILLION RUPEES AND IS FULLY INSURED

BRIEF-Suven Pharmaceuticals Says Fire Occurred On April 26 At Jeedimetla Facility

* FIRE INCIDENCE OCCURRED ON APRIL 26, 2020 AT JEEDIMETLA FACILITY

BRIEF-India's Suven Pharma Says Lockdown Causing Shortage Of Raw Materials

* INDIA LOCKDOWN DUE TO COVID HAS CAUSED A SHORTAGE OF RAW MATERIALS

BRIEF-Suven Life Sciences Dec Qtr Consol Net Profit Rises

* SUVEN LIFE SCIENCES LTD -DECLARED AN INTERIM DIVIDEND OF 2.50 RUPEES PER SHARE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up